Equitable Trust Co. Has $925,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Equitable Trust Co. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 34.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,900 shares of the medical device company’s stock after selling 6,343 shares during the period. Equitable Trust Co.’s holdings in DexCom were worth $925,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DXCM. Dynamic Advisor Solutions LLC grew its position in DexCom by 14.6% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 3,077 shares of the medical device company’s stock worth $206,000 after acquiring an additional 391 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its position in DexCom by 290.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,387 shares of the medical device company’s stock worth $227,000 after acquiring an additional 2,520 shares during the last quarter. Valeo Financial Advisors LLC grew its position in DexCom by 31.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 10,041 shares of the medical device company’s stock worth $673,000 after acquiring an additional 2,424 shares during the last quarter. Gateway Investment Advisers LLC grew its position in DexCom by 9.1% during the 3rd quarter. Gateway Investment Advisers LLC now owns 8,832 shares of the medical device company’s stock worth $592,000 after acquiring an additional 740 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in DexCom by 39.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock worth $823,000 after acquiring an additional 3,474 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $88.27 on Tuesday. The stock’s fifty day simple moving average is $81.76 and its 200 day simple moving average is $75.11. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a market capitalization of $34.48 billion, a PE ratio of 52.86, a PEG ratio of 2.26 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Citigroup increased their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Royal Bank of Canada decreased their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. increased their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $98.41.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock valued at $3,628,069 in the last 90 days. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.